A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the
efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab
or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be
performed at 105 weeks. The participants who do not enter open-label extension will enter for
a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).